Handelsavisen
prelaunch
Companies Healthcare 049960.KQ
04
049960.KQ KOSDAQ Pharmaceuticals

049960.Kq

$17 000,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
3,75 %
Op margin
14,9 %
ROE
7,7 %
Net margin
19,1 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

Business. The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
7,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 049960.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 049960.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a strong capital structure, with a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. Its liquidity position is characterized as medium, with a current ratio of 21.34, suggesting a high level of short-term liquidity. However, the company has a negative net cash position after subtracting total debt, which may raise concerns about its ability to meet short-term obligations.

    In terms of profitability, the company demonstrates a return on equity (ROE) of 7.69% and a return on assets (ROA) of 7.41%, both of which are strong indicators of efficient use of equity and assets. These figures suggest the company is performing well relative to industry standards, although specific comparisons to cohort medians are not available in the provided data.

    The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess revenue concentration or geographic exposure. However, the absence of detailed segment data may indicate a relatively concentrated business model or a lack of public disclosure on this matter.

    The company's growth trajectory is not explicitly outlined in the provided data, but its strong operating and net income figures suggest a stable and potentially growing business. The absence of detailed outlook data for the current and next fiscal years limits the ability to assess future growth expectations.

    The company's risk profile is characterized by a low dilution potential and a medium liquidity risk. The negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. No specific dilution sources are identified in the provided data, and the likelihood of near-term dilution is assessed as low.

    Recent events, such as filings and transcripts, are not detailed in the provided data, so it is not possible to assess the impact of recent developments on the company's financial position or strategic direction.

    Key takeaways
    • The company has a strong capital structure with no long-term debt and a high current ratio.
    • The company's profitability is robust, with a high return on equity and return on assets.
    • The company's liquidity position is medium, with a negative net cash position after subtracting total debt.
    • The company's risk profile is characterized by low dilution potential and medium liquidity risk.
    • The company's growth trajectory is not explicitly outlined, but its strong operating and net income figures suggest a stable and potentially growing business.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $17 000,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $131.64B
    Net cash
    -$425.4M
    Current ratio
    21.3
    Debt / equity
    0.0
    ROA
    7.4%
    ROE
    7.7%
    Cash conversion
    110.0%
    CapEx / revenue
    -6.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin14,9 %Above median
    Net Margin19,1 %Above P75
    ROE7,7 %Above median
    Capex / Rev-6,0 %Below median
    D/E0,00Above P75
    Cash Conv1,10Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 049960.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    049960.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage